The aims of this study were to investigate the prevalence of ED in Chinese men with type 2 diabetes mellitus, and evaluate the efficacy and safety of sildenafil citrate in these patients. Patients from 42 outpatient diabetes clinics with type 2 diabetes mellitus and ED as defined by the International Index of Erectile Function (IIEF)-5 were studied. Participants with ED received three doses (100 mg each) of sildenafil citrate for use over 3 months. Efficacy of sildenafil citrate was assessed using the IIEF-5 and the Global Efficacy Questionnaire (GEQ). Adverse events were recorded by patients in a daily diary. A total of 5477 participants were evaluated, and 75.2% had ED. Age, duration of diabetes and glycosylated hemoglobin (HbA 1 c) 46.5% were independently and significantly associated with the presence and degree of ED. Patients who received pharmacotherapy (N ¼ 389) reported significant improvements. The rate of erections as determined by the GEQ was also significantly improved following treatment. ED is a common complication in Chinese men with type 2 diabetes mellitus, and certain risk factors are associated with the presence of ED and severity. Sildenafil citrate is a safe and effective treatment for these patients.
Introduction
ED is defined as the inability to attain or maintain erection sufficient to permit satisfactory sexual performance. 1 ED is a common health problem, affecting more than 100 million men worldwide, 2 and can significantly impair quality of life, including spousal relationship, family life and psychological well-being.
When compared with the general population, the onset of ED is earlier and the prevalence is higher in patients with diabetes mellitus (DM), with a reported prevalence of 435%. [3] [4] [5] [6] [7] [8] In the Massachusetts Male Aging Study, the age-adjusted probability of ED was three times greater in subjects with diabetes than in those without diabetes. 2 Despite the high prevalence of ED in men with DM, it is often overlooked or inadequately treated compared with other diabetic complications.
Aging and depression are two of the major causes of ED in the general population. 1, 6, 9 In addition to the general causes, ED in diabetic patients is often associated with systemic disorders including atherosclerosis, endothelial dysfunction and neuropathy. 7, [10] [11] [12] In China, the prevalence of ED was reported to be 73.1% in the general population, whereas it was 84.5% in subjects with cardiovascular disease. 13 Medical management of ED has progressed significantly in the past decade, and oral PDE5 inhibitors have become the first-line treatment option. [14] [15] [16] PDE5 is a key phosphodiesterase in the corpus cavernosum and vascular smooth muscle, regulating in part the process of detumescence by catabolism of cyclic guanosine monophosphate. Sildenafil citrate is an orally active, selective inhibitor of PDE5, and its administration results in the initiation and maintenance of erection. 17, 18 Clinical studies have revealed sildenafil to be well tolerated with an overall efficacy of 480% in subjects with ED caused by various etiologies. 19 Furthermore, efficacy in patients with diabetes has been reported.
In the present clinical study, we investigated the prevalence of ED in non-institutionalized men with type 2 DM in China and studied the efficacy and safety of sildenafil citrate for the treatment of ED in this population. In addition, the risk factors associated with ED were evaluated. This study represents the first large-scale epidemiologic study of ED in Chinese men with type 2 DM.
Materials and methods

Study participants
This study was conducted in the outpatient diabetes clinics of 42 university-based medical schools and teaching hospitals in China (including 6 hospitals in Beijing, 4 in Tanjin, 4 in Chendu, 7 in Shanghai, 7 in Guangzhou, 6 in Shenyang, 4 in Wuhan, 3 in Hangzhou and 2 in Nanjing). The distribution of patients among participating hospital clinics ranged from 1 patient to 309 patients in a single clinic population. Adult Chinese males with type 2 DM underwent screening by routine medical history, physical examination and laboratory tests. Fasting blood glucose (FBG) levels were determined by the glucose oxidase method. Informed consent was obtained from each subject, and the study protocol was approved by the internal review board of the Chinese PLA General Hospital as well as the independent ethics committee of the Chinese PLA General Hospital. Demographic data were not recorded for patients who were initially recruited but who then decided not to participate and did not sign the consent form.
The participants included in this study were married men who met the American Diabetes Association criteria for type 2 diabetes. 22 Diabetic patients with ED had symptoms of ED for 43 months. Medications for DM, hypertension or other medical disorders were not discontinued during the study.
The exclusion criteria for the patients were: anatomical abnormalities of the genitals (for example, penile fibrosis) that impaired erection; a primary diagnosis of concomitant sexual dysfunction (for example, lowered libido); significant mental disorder; history of severe hematological, renal or hepatic disease; history of alcoholism or substance abuse within the past 12 months; history of stroke or myocardial infarction within the past 6 months; serious cardiovascular disease within the past 6 months, including heart failure, unstable angina pectoris or life-threatening arrhythmia; abnormal blood pressure (BP o90/50 mm Hg, systolic blood pressure (SBP) 4170 mm Hg or diastolic blood pressure (DBP) 4100 mm Hg at rest); history of malignant hypertension; use of medications that may cause ED or those with nitrate formulations (for example, oral, patch, sublingual and sprays); and a history of retinal uveitis. Patients who were regularly taking male hormones, chlorine trazodone or other drugs, or who used vacuum devices, intracavernous injections or a medicated urethral system for erections and did not intend to stop these treatments during the study period were also excluded. In addition, patients with signs or symptoms of hypogonadism were excluded. Because determination of testosterone levels is difficult in China, patients with any evidence of hypogonadism (reduced or loss of libido, reduced quality and frequency of erections, mood swings, depression and irritability, reduced cognitive function, reduced motivation, fatigue, reduced physical strength and endurance, sleep disturbances, hot flashes and sweats, subfertility, decreased body hair, slow beard growth and gynecomastia) were excluded.
Detecting and treating ED ED was defined as the inability to attain and/or maintain erection sufficient to permit satisfactory sexual intercourse. 1 The International Index of Erectile Function-5 (IIEF-5) questionnaire, 23 a validated and self-administered questionnaire, was used for clinical assessment of the presence and severity of ED. The IIEF-5 assesses erectile function, intercourse satisfaction, orgasmic function, sexual desire and overall satisfaction. 23 According to the diagnostic criteria of the IIEF-5, subjects with a total IIEF-5 score p21 were diagnosed with ED. 7 ED was categorized as severe (IIEF-5 score o7), moderate (IIEF-5 score X7 and o12) or mild (IIEF-5 score 12-21). If the participants were previously diagnosed with ED, the duration of ED and current and past therapies were recorded. After enrollment, all previous treatments for ED were discontinued at least 1 month before treatment.
Subjects with DM who met the diagnostic criteria for ED were given appropriate treatment based on their clinical condition and desire. Participants with ED received a total of three doses (100 mg each) of sildenafil citrate (Viagra, Pfizer, USA) for use over 3 months; each dose was administered as needed within the study period. Subjects treated with sildenafil citrate were asked to maintain a personal diary in order to record the occurrence of adverse events. After the treatment period, participants were evaluated at follow-up and completed two questionnaires, the IIEF-5 and the Global Evaluation Questionnaire (GEQ), 20 to assess sildenafil citrate efficacy. Follow-up was conducted at the end of the treatment period and 3 months following the discontinuation of sildenafil citrate. The safety and side effects of sildenafil citrate were evaluated based upon information recorded in the patient diaries.
Statistical analysis
Because continuous variables were in skewed distributions, all continuous data were presented as medians (interquartile range). For continuous ED, diabetes and Viagra G Yang et al variables, the Mann-Whitney U-test was used to examine the differences between participants with and without ED; the Kruskal-Wallis test was utilized to assess differences in severity among the participants with ED. The post hoc analysis of factors found significant using the Kruskal-Wallis test was performed using the Mann-Whitney test. Categorical variables were presented as percentages and were analyzed using the w 2 test or Fisher's exact test. Factors with P-values of o0.2 upon univariate analysis were analyzed by multivariate analysis. To identify potential risk factors for ED, stepwise binary logistic regression analysis was implemented; stepwise ordinal logistic regression analysis was performed to determine risk factors for severe ED. Because SBP and DBP are highly correlated, these two variables were placed into different multiple logistic regression models. The association between risk factors and outcome was analyzed by determining the odds ratios (ORs) with 95% confidence intervals (CIs). A two-sided P-value of o0.05 was defined as statistically significant. The level of significance was reduced to P ¼ 0.017 for post hoc analysis. All statistical analyses were performed using SAS statistical software, version 9.1.3 (SAS, Cary, NY, USA).
Results
Patient characteristics and prevalence of ED
A total of 6193 patients were recruited into this study, and the mean patient age was 54.2 ± 11.5 years. After excluding 716 patients with unknown ED status, 5477 patients were enrolled and analyzed.
Finally, 4113 patients had ED as determined by IIEF-5 score, and 279 of these patients received pharmacologic treatment. The characteristics of patients with ED were compared with those without ED ( Table 1) . Of the participants, 2598 (47.4%) were smokers and 1057 (19.3%) reported drinking alcohol.
Of the enrolled subjects, 89% completed the IIEF-5 questionnaire, and the average IIEF-5 score was 16.2 ± 6.1 (normal 421). As determined by IIEF-5 score, 75.1% of the participants had ED: 497 (9.1%) had severe ED, 944 (17.2%) had moderate ED and 2672 (48.9%) had mild ED. When compared with patients without ED, those with ED were significantly older and had significantly higher SBP, DBP and FBG. In addition, significantly more patients with ED had hypertension and heart disease. The ED group also displayed significantly longer durations of diabetes, hypertension and heart disease, as well as lower body mass index.
Multiple logistic regression analysis for ED risk factors Risk factors for ED in this patient population were also determined by multiple logistic regression analysis (Table 2) . Age (OR ¼ 1.09; 95% CI 1.08-1.10; Po0.001) and FBG (OR ¼ 1.03; 95% CI 1.01-1.05; P ¼ 0.006) were significant risk factors for ED; however, increased body mass index (OR ¼ 0.98; 95% CI 0.96-0.99; P ¼ 0.016) was associated with a reduced risk of ED. In addition, regular alcoholic beverage consumption was also a significant risk factor for ED (OR ¼ 1.23; 95% CI 1.03-1.46; P ¼ 0.021). Finally, hypertension and heart disease were significant risk factors for ED (OR ¼ 1.32; 95% 
Patient characteristics and ED severity
The associations between the severity of ED and patient characteristics were determined by univariate analysis (Table 3 ). Age and duration of DM increased with severity of ED. When compared with patients with moderate or severe ED, those with mild ED had lower SBP and DBP, and fewer patients with mild ED had hypertension or heart disease. Furthermore, among patients with hypertension or heart disease, shorter duration of either disease was observed in the group with mild ED. The body mass index and percentage of smokers were significantly higher in the group of patients with mild ED when compared with the groups with moderate or severe ED.
Risk factors associated with severe ED
In the patients with ED, the risk factors associated with severe ED were determined by stepwise ordinal logistic regression analysis ( ED, diabetes and Viagra G Yang et al ED were not assessed in the multivariate analysis because it was eliminated from the stepwise ordinal logistic regression model.
Efficacy and safety of sildenafil citrate
Of the 4113 patients with ED, 389 patients (9.4%) agreed to receive pharmacologic treatment with sildenafil citrate, consisting of three doses (100 mg each) for use over 3 months. The average patient age was 52 ± 12 years; blood pressure 127 ± 12/ 79±8 mm Hg; FBG 7.7±2.6 mmol/l; and glycosylated hemoglobin (HbA 1 c) 7.68 ± 1.79%. After pharmacologic treatment, the patients were evaluated with the IIEF-5 and GEQ questionnaires to assess the efficacy of sildenafil citrate. The total IIEF-5 score and the scores of each IIEF-5 question were significantly improved compared with the corresponding scores before treatment (data not shown).
In addition, marked improvements in the scores of patients with severe or moderate ED were observed, with scores significantly higher than those of normal patients ( Figure 1 ). The GEQ revealed that erectile function was improved in 319 patients (84%) following treatment with sildenafil citrate.
To assess the long-term effects of sildenafil citrate, patients were re-evaluated 3 months after treatment was discontinued. The average IIEF-5 score remained significantly higher than observed before treatment. In addition, 305 patients (86.4%) reported improved erectile function based on the GEQ questionnaire. Thus, improvements in erectile function were maintained even after sildenafil citrate was discontinued.
A total of 37 adverse events were recorded by 25 patients during treatment with sildenafil citrate. Of these events, 28 episodes in 20 patients were possibly related to sildenafil citrate, including flushing (17 episodes), headache (7 episodes), palpitations (2 episodes) and dry mouth (2 episodes). Most adverse events were mild and well tolerated. Three episodes of adverse events (one episode each of headache, flushing and hypertension) were moderate; the patient who complained of flushing and elevated blood pressure discontinued sildenafil citrate treatment. Finally, two episodes occurring after sildenafil administration were considered serious. One patient was admitted to the hospital after the onset of a headache, but it was selflimited and resolved soon after hospitalization. Another patient experienced palpitations and was admitted to the hospital for evaluation of diabetic complications and adjustment of blood glucose control regimen.
Discussion
This study is the first to document the prevalence of ED in Chinese men with type 2 DM using a largescale survey. Among the 5477 participants, the prevalence of ED was 75.2%. Age and duration of DM were significantly associated with the presence and severity of ED. In addition, age, FBG, hypertension and heart disease were significant risk factors for ED. Furthermore, patients with ED who received pharmacotherapy showed significant improvements in IIEF-5 scores, and minimal adverse events were reported.
Because this study was conducted in the outpatient diabetes clinics of 42 university-based medical schools and teaching hospitals across China and hospitalized patients were excluded, the study population is more representative of type 2 diabetic patients nationwide seeking outpatient medical care when compared with previous studies. For example, a regional study of ED prevalence in 486 Chinese men with diabetes was conducted in a community hospital clinic in Hong Kong. 24 When compared with this regional study, participants in the present study were more representative of the overall Chinese population with DM. In addition, in the present study the age range was 17.2-93.2 years, which spans the majority of age groups in which type 2 diabetes most often occurs, and 62% of the subjects were o60 years of age. Because age is a risk factor for ED, 9 participant age was important to assess for determining whether ED prevalence was associated with diabetes or occurs as a natural process of aging.
The overall prevalence of ED was 75% in this study. Not surprisingly, it was higher than that reported for the general Chinese population, 25 and also higher than reported in studies of general populations in other Asian, 26 as well as Western countries. 2, 26, 27 Although our results were similar to those of a study conducted in France, which observed a 71% prevalence, 28 they were higher than those reported in Hong Kong (64%), 24 Japan (60%) 29 and Italy (37%), 30 and lower than reported by the Israel Diabetes Research Group Investigators (86.5%). 31 These differences may be attributable to the various definitions of ED use, 24, 29, 30 as well as differing diagnostic criteria 24, 30, 32 or sample sizes.
24,29
Figure 1 Comparison of patients with various degrees of ED before and after treatment.
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Reduced blood flow to the corpus cavernosum is the primary pathophysiological mechanism of ED and may be because of autonomic nerve 33 and endothelial 2,34 dysfunction, which are further compromised in individuals with DM. 35, 36 Elevated homocysteine concentrations, which directly influence NO levels, have been reported in patients with DM and represent an independent risk factor for ED. 37 Conversely, improvements in endothelial function 38 and ED 39 have been reported after weight loss in obese men with metabolic syndrome.
In this study, we used IIEF-5 to determine the presence and severity of ED. The IIEF-5 questionnaire is a validated, internationally established index of ED that covers five components of sexual function, including erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction. 23, 27, 40 The IIEF-5 questionnaire is easily self-administered and can reliably determine the effectiveness of ED treatments. 40, 41 In our study population, approximately 50, 17 and 9% of participants with ED had mild, moderate and severe ED, respectively, which is significantly higher than 29, 2.2 and 1.3%, respectively, reported by Ponholzer et al., 27 who also used the IIEF-5 to assess ED in their study of the general population in Austria.
Logistic regression analysis revealed that age was an independent factor significantly associated with ED. Although age is a well-known risk factor for ED in the general population, ED occurred earlier and was more severe in diabetic subjects; ED was found in 48% of the patients o40 years of age, and increased to 65% in those aged 40-50 years, 79% in those aged 50-60 years and 93% in those aged 460 years. These results are much higher than those observed in the general Chinese population in Shanghai, China, where the prevalence of ED was 33, 36 and 74% in men aged 40-49, 60 and 70 years, respectively. 42 Moreover, the prevalence of severe ED in our diabetic population was higher than that in similar age groups in the general population (3.4 vs 0.5% for men o50 years of age and 7 vs 3% for men o60 years of age). 27 In addition to age, duration of diabetes was also independently associated with the presence and severity of ED. More than 60% of patients experienced ED within 2 years of diagnosis of DM. Both the incidence and severity of ED significantly increased with duration of diabetes. Furthermore, the prevalence of ED was significantly associated with glycemic control; ED was significantly higher in patients with HbA 1 c 46.5% when compared with those with HbA 1 c p6.5%. Similarly, the presence of ED was independently associated with glycemic control (OR ¼ 1.64; Po0.001). Despite differences in the overall prevalence of ED between our study and other reports, associations between age and duration of diabetes and ED are in accord with previous studies. 2, 24, [29] [30] [31] [32] [43] [44] [45] Hypertension and vascular disease have been reported to be risk factors for ED. 2, 27, 28, 44, [46] [47] [48] [49] In addition, the prevalence of ED is reported to be higher in men taking certain medications, including hypoglycemic agents, antihypertensive or cardiac drugs, diuretics and antidepressants. 2, [50] [51] [52] [53] We also observed a higher prevalence of ED in patients who had hypertension or cardiovascular disease. In addition, patients who were taking antihypertensive drugs, medications for glycemic control, diuretics, b-blockers and calcium antagonists had a higher prevalence of ED when compared with those not taking these medications; however, we could not confirm these to be independent risk factors associated with ED by logistic regression analysis. These results are in accord with those reported by Chew et al., 40 Roth et al. 44 and Jaffe et al.
54
No association between smoking and the prevalence of ED was observed in our study, which is consistent with some reports, 31, 45, 55 whereas contradictory to others. 30 In addition, no significant difference in the prevalence of ED in smokers when compared with those who were passively exposed to smoke was observed in the Massachusetts Male Aging Study, 1994. 2 However, a follow-up study revealed that smoking and passive exposure to smoke were significant predictors of the occurrence of ED, 56 suggesting that smoking has an important role in the occurrence of ED.
Although ED is a common problem in diabetic subjects, it is not often discussed between patients and their doctors. In this study population, only 5% of those diagnosed with ED had been treated. The low proportion of patients treated for ED may be attributable to fewer complaints of sexual dysfunction as a result of cultural influences, as well as reduced awareness of ED by clinicians. The effect of cultural influence is highlighted by the fact that only 9.5% of our patients with ED were willing to receive treatment. Chew et al. 46 also reported that only 11.6% of patients with ED sought treatment in the general population in Australia.
In this study, the efficacy of sildenafil citrate was evaluated by both IIEF-5 and GEQ, and improvements in 84% of the respondents were observed during the 3 months of treatment. These improvements were maintained for an additional 3 months after sildenafil citrate was discontinued. Although the effectiveness of sildenafil citrate was similar to that reported in patients with ED caused by various etiologies, 19 it was higher than that reported by other studies of diabetic patients with ED. 20, 57 The high efficacy of sildenafil citrate in our patients may be related to the high percentage of mild ED in our treated subjects. Compared with baseline, sildenafil citrate treatment improved the scores associated with erectile function (questions 2-4 of the IIEF-5) by 77.5, 79.8 and 67.2%, respectively (data not shown). Because we did not include a placebo control group in this study, the significant ED, diabetes and Viagra G Yang et al improvement of erectile function may be a result of other factors in addition to sildenafil citrate. However, significantly different effects of sildenafil citrate verses placebo have been reported by Goldstein et al. 19 In their placebo-controlled study, successful results in sexual intercourse were significantly higher in patients treated with sildenafil citrate when compared with those receiving placebo. Thus, improved erectile function most likely reflects the effect of sildenafil citrate in diabetic patients with ED.
The most frequently reported adverse events associated with sildenafil citrate treatment included flushing and headache, which is consistent with the known pharmacological effects of this drug. 19 Most of the adverse events were mild and transient, which is similar to previous studies of diabetic patients treated with sildenafil citrate for ED. 58 These results indicate that sildenafil citrate is safe for the treatment of ED in diabetic subjects.
There is a limitation of the study that should be considered. Our study did not determine testosterone levels in patients. Although determination of testosterone level is useful to rule out hypogonadism, patients were excluded from the analysis if they had any evidence of hypogonadism. All patients studied desired to achieve erection and have intercourse but could not, and thus we do not believe that measuring testosterone levels would have altered the patient population studied or the results. In addition, the prevalence of low sexual desire in diabetic patients is far less than that in the non-diabetic population. In most diabetic patients, ED is related to the nerve and blood vessel complications caused by diabetes itself and, as the diabetic population was the main population being investigated in this study, we did not carry out further biochemical examinations (for example, testosterone levels) related to hypogonadism and simply excluded any patient who may have had this condition.
In summary, this report represents the largest epidemiological study to assess the prevalence of ED in Chinese men with type 2 DM to date. ED is one of the most frequent and early complications of DM, and is often neglected in the Chinese diabetic population. The most important risk factors for the presence and severity of ED in this population were age, duration of DM and poor glycemic control. Sildenafil citrate was found to be safe and effective for the treatment of ED in the study population. Because of the high prevalence of ED, clinicians should provide early screening and treatment for ED to patients with DM.
